Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens

Science Translational Medicine

Volumn 5, Issue 185, 2013, Pages

  Raby, Anne Catherine ^a   Holst, Benjamin ^a   Le Bouder, Emmanuel ^a   Diaz, Constantino ^b   Ferran, Edgardo ^b   Conraux, Laurence ^b   Guillemot, Jean Claude ^b   Coles, Barbara ^a   Kift Morgan, Ann ^a   Colmont, Chantal S ^a   Szakmany, Tamas ^a   Ferrara, Pascual ^b   Hall, Judith E ^a   Topley, Nicholas ^a   Labéta, Mario O ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 8; LEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL PERITONITIS; BIOCHEMISTRY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE MODEL; DRUG TARGETING; EX VIVO STUDY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; PATHOGEN CLEARANCE; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; SEPSIS; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STAPHYLOCOCCUS EPIDERMIDIS; TH1 CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD14; BACTERIA; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; IMMUNITY; IMMUNOSUPPRESSION; INFLAMMATION; LIGANDS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; MICE; MICE, INBRED C57BL; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; PEPTIDES; PERITONITIS; PHAGOCYTES; PROTEIN BINDING; PROTEINS; SEPSIS; TOLL-LIKE RECEPTOR 2;

EID: 84878314272     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005544     Document Type: Article

References (41)

1. T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
2. F. Y. Liew, D. Xu, E. K. Brint, L. A. O'Neill, Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5, 446-458 (2005).
3. H. Kanzler, F. J. Barrat, E. M. Hessel, R. L. Coffman, Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552-559 (2007).
4. S. M. Opal, Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin. Respir. Crit. Care Med. 32, 569-580 (2011).
5. N. J. Shubin, S. F. Monaghan, A. Ayala, Anti-inflammatory mechanisms of sepsis. Contrib. Microbiol. 17, 108-124 (2011).
6. A. Iwasaki, R. Medzhitov, Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
7. A. Dunne, N. A. Marshall, K. H. Mills, TLR based therapeutics. Curr. Opin. Pharmacol. 11, 404-411 (2011).
8. A. Haziot, E. Ferrero, F. Köntgen, N. Hijiya, S. Yamamoto, J. Silver, C. L. Stewart, S. M. Goyert, Resistance to endotoxin shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice. Immunity 4, 407-414 (1996).
9. A. Yoshimura, E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, D. Golenbock, Cutting edge: Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163, 1-5 (1999).
10. C. L. Baumann, I. M. Aspalter, O. Sharif, A. Pichlmair, S. Blüml, F. Grebien, M. Bruckner, P. Pasierbek, K. Aumayr, M. Planyavsky, K. L. Bennett, J. Colinge, S. Knapp, G. Superti-Furga, CD14 is a coreceptor of Toll-like receptors 7 and 9. J. Exp. Med. 207, 2689-2701 (2010).
11. H. K. Lee, S. Dunzendorfer, K. Soldau, P. S. Tobias, Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 24, 153-163 (2006).
12. E. A. Frey, D. S. Miller, T. G. Jahr, A. Sundan, V. Bazil, T. Espevik, B. B. Finlay, S. D. Wright, Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176, 1665-1671 (1992).
13. J. J. Durieux, N. Vita, O. Popescu, F. Guette, J. Calzada-Wack, R. Munker, R. E. Schmidt, J. Lupker, P. Ferrara, H. W. Ziegler-Heitbrock, The two soluble forms of the lipopolysaccharide receptor, CD14: Characterization and release by normal human monocytes. Eur. J. Immunol. 24, 2006-2012 (1994).
14. M. O. Labéta, K. Vidal, J. E. Nores, M. Arias, N. Vita, B. P. Morgan, J. C. Guillemot, D. Loyaux, P. Ferrara, D. Schmid, M. Affolter, L. K. Borysiewicz, A. Donnet-Hughes, E. J. Schiffrin, Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J. Exp. Med. 191, 1807-1812 (2000).
15. M. Triantafilou, K. Miyake, D. T. Golenbock, K. Triantafilou, Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115, 2603-2611 (2002).
16. A. C. Raby, E. Le Bouder, C. Colmont, J. Davies, P. Richards, B. Coles, C. H. George, S. A. Jones, P. Brennan, N. Topley, M. O. Labéta, Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J. Immunol. 183, 506-517 (2009).
17. E. LeBouder, J. E. Rey-Nores, N. K. Rushmere, M. Grigorov, S. D. Lawn, M. Affolter, G. E. Griffin, P. Ferrara, E. J. Schiffrin, B. P. Morgan, M. O. Labéta, Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J. Immunol. 171, 6680-6689 (2003).
18. N. J. Gay, M. Gangloff, Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 76, 141-165 (2007).
19. E. J. Giamarellos-Bourboulis, What is the pathophysiology of the septic host upon admission? Int. J. Antimicrob. Agents 36, S2-S5 (2010).
20. G. P. Otto, M. Sossdorf, R. A. Claus, J. Rödel, K. Menge, K. Reinhart, M. Bauer, N. C. Riedemann, The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 (2011).
21. W. Ertel, J. P. Kremer, J. Kenney, U. Steckholzer, D. Jarrar, O. Trentz, F. W. Schildberg, Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85, 1341-1347 (1995).
22. G. Huang, Y. Wang, H. Chi, Regulation of TH 17 cell differentiation by innate immune signals. Cell. Mol. Immunol. 9, 287-295 (2012).
23. A. Pfeiffer, A. Böttcher, E. Orsó, M. Kapinsky, P. Nagy, A. Bodnár, I. Spreitzer, G. Liebisch, W. Drobnik, K. Gempel, M. Horn, S. Holmer, T. Hartung, G. Multhoff, G. Schütz, H. Schindler, A. J. Ulmer, H. Heine, F. Stelter, C. Schütt, G. Rothe, J. Szöllôsi, S. Damjanovich, G. Schmitz, Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur. J. Immunol. 31, 3153-3164 (2001).
24. M. Triantafilou, F. G. Gamper, R. M. Haston, M. A. Mouratis, S. Morath, T. Hartung, K. Triantafilou, Membrane sorting of Toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J. Biol. Chem. 281, 31002-31011 (2006).
25. J. I. Kim, C. J. Lee, M. S. Jin, C. H. Lee, S. G. Paik, H. Lee, J. O. Lee, Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J. Biol. Chem. 280, 11347-11351 (2005).
26. S. Adams, Toll-like receptor agonists in cancer therapy. Immunotherapy 1, 949-964 (2009).
27. H. Lu, W. M.Wagner, E. Gad, Y. Yang, H. Duan, L. M. Amon, N. VanDenend, E. R. Larson, A. Chang, H. Tufvesson, M. L. Disis, Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J. Immunol. 184, 5360-5367 (2010).
28. J. S. Weber, H. Zarour, B. Redman, U. Trefzer, S. O'Day, A. J. van den Eertwegh, E. Marshall, S. Wagner, Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115, 3944-3954 (2009).
29. P. L. Witt, P. S. Ritch, D. Reding, T. L. McAuliffe, L. Westrick, S. E. Grossberg, E. C. Borden, Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 53, 5176-5180 (1993).
30. A. Haziot, G. W. Rong, X. Y. Lin, J. Silver, S. M. Goyert, Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J. Immunol. 154, 6529-6532 (1995).
31. S. M. Opal, J. E. Palardy, N. Parejo, R. L. Jasman, Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Crit. Care Med. 31, 929-932 (2003).
32. K. Reinhart, T. Glück, J. Ligtenberg, K. Tschaikowsky, A. Bruining, J. Bakker, S. Opal, L. L. Moldawer, T. Axtelle, T. Turner, S. Souza, J. Pribble, CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med. 32, 1100-1108 (2004).
33. J. Schimke, J. Mathison, J. Morgiewicz, R. J. Ulevitch, Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. U.S.A. 95, 13875-13880 (1998).
34. C. A. Spek, A. Verbon, H. Aberson, J. P. Pribble, C. J. McElgunn, T. Turner, T. Axtelle, J. Schouten, T. Van Der Poll, P. H. Reitsma, Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. J. Clin. Immunol. 23, 132-140 (2003).
35. R. S. Hotchkiss, C. M. Coopersmith, J. E. McDunn, T. A. Ferguson, The sepsis seesaw: Tilting toward immunosuppression. Nat. Med. 15, 496-497 (2009).
36. C. Meisel, J. C. Schefold, R. Pschowski, T. Baumann, K. Hetzger, J. Gregor, S. Weber-Carstens, D. Hasper, D. Keh, H. Zuckermann, P. Reinke, H. D. Volk, Granulocyte-macrophage colonystimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640-648 (2009).
37. M. M. Levy, M. P. Fink, J. C. Marshall, E. Abraham, D. Angus, D. Cook, J. Cohen, S. M. Opal, J. L. Vincent, G. Ramsay; SCCM/ESICM/ACCP/ATS/SIS, 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256 (2003).
38. S. M. Opal, New perspectives on immunomodulatory therapy for bacteraemia and sepsis. Int. J. Antimicrob. Agents 36 (Suppl. 2), S70-S73 (2010).
39. W. C. Chan, P. D. White, Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Oxford Univ. Press, Oxford, 2000).
40. J. E. Rey Nores, A. Bensussan, N. Vita, F. Stelter, M. A. Arias, M. Jones, S. Lefort, L. K. Borysiewicz, P. Ferrara, M. O. Labéta, Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur. J. Immunol. 29, 265-276 (1999).
41. M. S. Jin, S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, J. O. Lee, Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130, 1071-1082 (2007).